BP-lowering treatment for patients with type 2 diabetes associated with improved mortality
the ONA take:
According to a new study published in JAMA, researchers have found that blood pressure-lowering treatment in patients with type 2 diabetes is associated with a decreased risk of cardiovascular disease and cardiovascular disease events, coronary heart disease events, and mortality.
For the meta-analysis, researchers identified 40 randomized controlled trials of blood pressure-lowering therapy conducted between 1966 and 2014 that included over 100,000 participants in order to investigate the associations between blood pressure-lowering treatment and cardiovascular disease in patients with type 2 diabetes.
Researchers found that each 10mm Hg lowering of systolic blood pressure was linked with a lower risk of cardiovascular disease events, coronary heart disease events, mortality, stroke, retinopathy, and albuminuria. Researchers did not find a significant difference in associations between blood-pressure lowering treatments and outcomes except for heart failure and stroke.
Results showed that blood pressure reduction below 130mm Hg was associated with a decreased risk of albuminuria, retinopathy, and stroke, but most outcomes had a decreased risk when systolic blood pressure was below 140mm Hg.
The findings supports current guideline recommendations that patients with type 2 diabetes be treated with antihypertensive therapy when their systolic blood pressure is above 140mm Hg.
Blood pressure-lowering treatment in patients with type 2 diabetes is associated with a decreased risk of cardiovascular disease.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|